AstraZeneca Aktie
WKN: 886715 / ISIN: US0463531089
04.09.2023 09:01:48
|
AstraZeneca's Calquence Approved In China For Chronic Lymphocytic Leukaemia
(RTTNews) - China's National Medical Products Administration approved AstraZeneca plc.'s (AZN, AZN.L) Calquence or acalabrutinib for the treatment of adult patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma who have received at least one prior therapy. Calquence is a next generation, selective Bruton's tyrosine kinase (BTK) inhibitor.
The approval was based on results from ASCEND global phase III trial and a phase I/II local trial, which showed 83.3% overall response rate in Chinese patients treated with Calquence.
Chronic lymphocytic leukaemia is the most prevalent type of adult leukaemia across the globe and represents approximately 6.4% of B-cell non-Hodgkin lymphoma patients in China.
Calquence is approved for the treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma in the US and Japan and is approved for the treatment of chronic lymphocytic leukaemia in the EU and in several other countries worldwide in the treatment-naïve and relapsed or refractory settings.
Calquence is also approved in the US, China and several other countries for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy. Calquence is not currently approved for the treatment of mantle cell lymphoma in Japan or the EU.
For More Such Health News, visit rttnews.com

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AstraZeneca PLC (spons. ADRs)mehr Nachrichten
28.07.25 |
Ausblick: AstraZeneca informiert über die jüngsten Quartalsergebnisse (finanzen.net) | |
23.07.25 |
Gewinne in New York: Börsianer lassen NASDAQ 100 steigen (finanzen.at) | |
22.07.25 |
AstraZeneca-Aktie höher: AstraZeneca stärkt US-Präsenz mit Milliarden-Investitionsprogramm (Dow Jones) | |
17.07.25 |
Aufschläge in New York: Gewinne im NASDAQ 100 (finanzen.at) | |
17.07.25 |
Aufschläge in New York: NASDAQ 100 zeigt sich am Mittag fester (finanzen.at) | |
16.07.25 |
AstraZeneca-Aktie im Minus: Anselamimab hat Studienziel nicht erreicht (Dow Jones) | |
14.07.25 |
Erste Schätzungen: AstraZeneca gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net) | |
04.07.25 |
AstraZeneca-Aktie höher: Summit Therapeutics und AstraZeneca sprechen über Ivonescimab-Deal (Dow Jones) |
Analysen zu AstraZeneca PLC (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
AstraZeneca PLC (spons. ADRs) | 61,50 | 0,00% |
|